From: A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study
Study group
(N = 1783)
Control group
(N = 1419)
OHSS events, n (%)
P-valuea
27 (1.5)
57 (4.0)
P < 0.0001
OHSS severity, n (%)
Mild/Grade I
Moderate/Grade II
Severe/Grade III
12 (0.7)
13 (0.7)
2 (0.1)
32 (2.3)
20 (1.4)
5 (0.4)